Please assess the completion status of the following clinical trial:

Trial Title: Hyperpolarized Carbon-13 Imaging of Metastatic Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men with bone-metastatic CRPC before starting the first dose of radium 223 therapy~* Laboratory requirements:~* Absolute neutrophil count (ANC) ≥ 1.5 x 109/L~* Platelet count ≥ 100 x109/L~* Hemoglobin ≥ 10.0 g/dL (100 g/L; 6.2 mmol/L)~* Total bilirubin level ≤ 1.5 institutional upper limit of normal (ULN)~* ASAT and ALAT ≤ 2.5 ULN~* • Creatinine ≤ 1.5 ULN~* Albumin \>25 g/L~* Eastern Cooperative Oncology Group Status of 0 or 1~Exclusion Criteria:~* Unable to give valid informed consent~* Contraindication for MRI as per Sunnybrook MRI questionnaire (Appendix 1).~* Claustrophobia~* Body mass index of less than 18.5 or greater than 32~* Congestive heart failure, a past or present medical history of clinically significant electrocardiogram (EKG) abnormalities, which may include QT prolongation, a family history of prolonged QT interval syndrome, or a myocardial infarction (MI) within the past 12 months with ensuing unstable EKG, or ongoing acute or chronic pulmonary bronchospastic disease, including a history of chronic obstructive pulmonary disease or asthma, with an exacerbation within the past year

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MRI w/ Hyperpolarized Pyruvate (13C) (Type: EXPERIMENTAL): Hyperpolarization of low natural abundance species such as 13C, when injected offers the potential of extracting metabolic information by real-time MR imaging of biochemical reactions within the body. The biochemical reactions, including lactate production, will be measured using MRI.

Based on this trial design, predict the completion outcome and termination type (if applicable).